

GI

FOR OUTSIDE THE US AND CANADA ONLY

LIAISON[®] Elastase-1

Treatment of maldigestion starts
with the right diagnosis.

Fecal Elastase-1 assay is an aid
in the diagnosis of pancreatic
exocrine insufficiency.

GASTROINTESTINAL DISEASES



DiaSorin

The Diagnostic Specialist

LIAISON® Elastase-1

Pancreatic insufficiency is the inability of the exocrine pancreas to produce and/or transport enough digestive enzymes to break down food in the intestine and facilitate absorption of nutrients. It typically occurs as a result of progressive pancreatic damage that may be caused by recurrent acute pancreatitis or by chronic pancreatitis due to a variety of conditions.

Failure in any of the digestive metabolic steps may be the result in pancreatic exocrine insufficiency (PEI). Current methods for evaluating digestion, such as fecal fat quantification and the ¹³C-mixed triglycerides test, are the most used and known tests but are complicated and sometimes need long execution times. With the introduction of the new automated chemiluminescence assay LIAISON® Elastase-1, testing is easier and quickly done avoiding complicated procedures and execution steps.

Key Assay features

Method	Quantitative Sandwich, 100 tests	Time to first result	30 minutes
Solid Phase / Conjugate	Monoclonal Antibodies to Pancreatic Elastase-1	Integral on board stability	56 days
Sample volume	40 µL extracted sample	Calibrators availability	2 Lyophilized
Range without dilution	0.2-800 µg/g	Calibration stability	28 days

Method Comparison

A total of 201 stool samples spanning the assay range were tested by the LIAISON® Elastase-1 and a commercial Elastase-1 assay following CLSI EP09-A3.

An agreement analysis was also performed relative to the respective assay cut-off values for the relevant medical decision points. Results are summarized in the tables below.

LIAISON® Elastase-1 Assay Concentration	Comparator Elastase-1 Assay Concentration			
	≥ 200 µg/g	199-100 µg/g (mild to moderate insufficiency)	<100 µg/g (severe insufficiency)	Total
≥ 200 µg/g (normal)	139	2	0	141
199-100 µg/g (mild to moderate insufficiency)	3	11	0	14
<100 µg/g (severe insufficiency)	0	1	45	46
Total	142	14	45	201

Agreement type	% Agreement	95% Confidence interval
≥ 200 µg/g (normal) agreement (136/141)	97.9%	94.0% - 99.6%
199-100 µg/g (mild to moderate insufficiency) agreement (55/61)	78.6%	49.2% - 95.3%
<100 µg/g (severe insufficiency) agreement (55/61)	100%	92.1% - 100%
Overall agreement (191/202)	97.0%	93.6% - 98.9%

Ordering information LIAISON®

LIAISON® Elastase-1	(code 319140)
LIAISON® Elastase-1 Control Set	(code 319141)
LIAISON® Q.S.E.T. Device Plus	(code 319060)
LIAISON® Q.S.E.T. Buffer	(code 319135)

Please visit: www.diasorin.com
for more information and updates

LIAISON® is a registered trademark of DiaSorin

Available on LIAISON®  and LIAISON® 

Product availability subject to required regulatory approval

Diasorin S.p.A

Via Crescentino SNC, 13040 Saluggia (VC) - Italy
www.diasorin.com